MascarenhasL, SiegelS, SpectorLet al.Malignant bone tumors in adolescents and young adultsCancer epidemiology in older adolescents and young adults 15–29 years of age, including SEER incidence and survival: 1975–2000 (NIH Pub. No. 06-5767)BleyerA, O'LearyM, BarrR, RiesLAG. Bethesda, MD: National Cancer Institute, 2006; 97–110.
2.
LadanyiM, LewisR, Garin-ChesaPet al.EWS rearrangement in Ewing's sarcoma and peripheral neuroectodermal tumor. Molecular detection and correlation with cytogenetic analysis and MIC2 expression. Diagn Mol Pathol., 1993; 2:141–146.
3.
BernsteinML, KovarH, PauussenMet al.Ewing Sarcoma Family of Tumors: Ewing Sarcoma of Bone and Soft Tissue and the Peripheral Primitive Neuroectodermal Tumors. Principles and Practice of Pediatric Oncology, 5thPizzoPA, PoplackDG. Philadelphia: Lippincott Williams & Wilkins, 2005; 1002–1032.
4.
NesbitME, GehanEA, BurgertEOet al.Multimodal therapy for the management of primary, non-metastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study. J Clin Oncol., 1990; 8:1664–1674.
5.
BurgertEO, NesbitME, GarnseyLAet al.Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: intergroup study IESS-II. J Clin Oncol., 1990; 8:1514–1524.
6.
GrierHE, KrailoMD, TarbellNJet al.Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med., 2003; 348:694–701.
7.
GranowetterL, WomerR, DevidasMet al.Dose-intensified compared with standard chemotherapy for non-metastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study. J Clin Oncol., 2009; 27:2536–2541.
8.
WomerRB, WestD, KrailoMDet al.Randomized comparison of every-two-week v. every-three-week chemotherapy in Ewing sarcoma family tumors (ESFT) [abstract]J Clin Oncol., 2008; 26:554a.
9.
BernsteinML, DevidasM, LafreniereDet al.Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group phase II study 9457—a report from the Children's Oncology Group. J Clin Oncol., 2006; 24:152–159.
10.
SaylorsRL, StineKC, SullivanJet al.Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol., 2001; 19:3463–3469.
11.
HunoldA, WeddelingN, PaulussenMet al.Topotecan, cyclophosphamide in patients with refractory or relapsed Ewing tumors. Pediatr Blood Cancer., 2006; 47:795–800.
